Tsumura Valuation Multiples

Tsumura Overview

About Tsumura

Tsumura & Co is a specialty and generic drug manufacturing company. The company generates the majority of its revenue through prescription Kampo products, followed by over-the-counter medicines. It promotes its products through educational support at medical schools and by hosting seminars for physicians and consumers. The company specializes in developing, producing, and marketing Kampo formulations that integrate traditional herbal knowledge with modern pharmaceutical science to address various health conditions.

Founded

1936

HQ

Employees

5.0K

Website

tsumura.co.jp

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $1B

EBITDA: $305M

EV

$2B

Valuation Multiples

Multiples.vc

Start free trial

Tsumura Financials

Tsumura reported last 12-month revenue of $1B and EBITDA of $305M.

In the same LTM period, Tsumura generated $588M in gross profit, $305M in EBITDA, and $168M in net income.

Tsumura P&L

In the most recent fiscal year, Tsumura reported revenue of $1B and EBITDA of $360M.

Tsumura expects next 12-month revenue of XXX and NTM EBITDA of XXX

Tsumura Stock Performance

Tsumura has current market cap of $2B, and enterprise value of $2B.

Tsumura's stock price is $23.57.

Tsumura Valuation Multiples

Tsumura trades at 1.7x EV/Revenue multiple, and 7.1x EV/EBITDA.

Tsumura Financial Valuation Multiples

As of April 19, 2026, Tsumura has market cap of $2B and EV of $2B.

Equity research analysts estimate Tsumura's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Tsumura has a P/E ratio of 10.4x.

Tsumura Margins & Growth Rates

Tsumura's revenue in the last 12 month grew by 9%.

Tsumura's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Tsumura's rule of 40 is 34% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Tsumura's rule of X is 47% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Tsumura Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Tsumura M&A Activity

Tsumura acquired XXX companies to date.

Last acquisition by Tsumura was on XXXXXXXX, XXXXX. Tsumura acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Tsumura Investment Activity

Tsumura invested in XXX companies to date.

Tsumura made its latest investment on XXXXXXXX, XXXXX. Tsumura invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).